Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD. It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salmeterol was first described in the literature in 1988. Salmeterol’s structure is similar to salbutamol’s with an aralkyloxy-alkyl substitution on the amine. Salmeterol was granted FDA approval on 4 February 1994. It is grouped under the following drug class(es): Beta-2 agonists and Bronchodilators. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Salmeterolum and salmeterolo. Its PubChem CID is 5152.
Salmeterol
| CAS No | 89365-50-4 |
|---|---|
| Molecular Formula | C25H37NO4 |
| Molecular Weight | 415.6 g/mol |
| Synonyms | 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.
The listed CAS number is 89365-50-4.
The listed molecular formula is C25H37NO4.
The listed molecular weight is 415.6 g/mol.
2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol.
The source lists Salmeterolum and salmeterolo.